Pre-pouch Ileitis is Associated with Development of Crohn's Disease-like Complications and Pouch Failure.


Journal

Journal of Crohn's & colitis
ISSN: 1876-4479
Titre abrégé: J Crohns Colitis
Pays: England
ID NLM: 101318676

Informations de publication

Date de publication:
22 Jun 2021
Historique:
pubmed: 11 12 2020
medline: 15 12 2021
entrez: 10 12 2020
Statut: ppublish

Résumé

It is unclear whether pre-pouch ileitis heralds an aggressive inflammatory pouch disease in patients with ileal pouch-anal anastomosis [IPAA]. We compared outcomes of patients with pouchitis and concomitant pre-pouch ileitis with those with pouchitis alone. Patients undergoing IPAA surgery for inflammatory bowel disease, who subsequently developed pouchitis with concomitant pre-pouch ileitis [pre-pouch ileitis group], were matched by year of IPAA surgery and preoperative diagnosis [ulcerative colitis or inflammatory bowel disease-unclassified] with patients who developed pouchitis alone [pouchitis group]. Primary outcomes were development of Crohn's disease [CD]-like complications [non-anastomotic strictures or perianal disease >6 months after ileostomy closure] and pouch failure. Secondary outcomes were need for surgical/endoscopic interventions and immunosuppressive therapy. Log-rank testing was used to compare outcome-free survival, and Cox regression was performed to identify predictors of outcomes. There were 66 patients in each group. CD-like complications and pouch failure developed in 36.4% and 7.6% patients in the pre-pouch ileitis group and 10.6% and 1.5% in pouchitis group, respectively. CD-like complications-free survival [log-rank p = 0.0002] and pouch failure-free survival [log-rank p = 0.046] were significantly lower in the pre-pouch ileitis group. The pre-pouch ileitis group had a higher risk of requiring surgical/endoscopic interventions [log-rank p = 0.0005] and immunosuppressive therapy [log-rank p <0.0001]. Pre-pouch ileitis was independently associated with an increased risk of CD-like complications (hazard ratio [HR] 3.8; p = 0.0007), need for surgical/endoscopic interventions [HR 4.1; p = 0.002], and immunosuppressive therapy [HR 5.0; p = 0.0002]. Pre-pouch ileitis is associated with a higher risk of complicated disease and pouch failure than pouchitis. It should be considered a feature of CD.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
It is unclear whether pre-pouch ileitis heralds an aggressive inflammatory pouch disease in patients with ileal pouch-anal anastomosis [IPAA]. We compared outcomes of patients with pouchitis and concomitant pre-pouch ileitis with those with pouchitis alone.
METHODS METHODS
Patients undergoing IPAA surgery for inflammatory bowel disease, who subsequently developed pouchitis with concomitant pre-pouch ileitis [pre-pouch ileitis group], were matched by year of IPAA surgery and preoperative diagnosis [ulcerative colitis or inflammatory bowel disease-unclassified] with patients who developed pouchitis alone [pouchitis group]. Primary outcomes were development of Crohn's disease [CD]-like complications [non-anastomotic strictures or perianal disease >6 months after ileostomy closure] and pouch failure. Secondary outcomes were need for surgical/endoscopic interventions and immunosuppressive therapy. Log-rank testing was used to compare outcome-free survival, and Cox regression was performed to identify predictors of outcomes.
RESULTS RESULTS
There were 66 patients in each group. CD-like complications and pouch failure developed in 36.4% and 7.6% patients in the pre-pouch ileitis group and 10.6% and 1.5% in pouchitis group, respectively. CD-like complications-free survival [log-rank p = 0.0002] and pouch failure-free survival [log-rank p = 0.046] were significantly lower in the pre-pouch ileitis group. The pre-pouch ileitis group had a higher risk of requiring surgical/endoscopic interventions [log-rank p = 0.0005] and immunosuppressive therapy [log-rank p <0.0001]. Pre-pouch ileitis was independently associated with an increased risk of CD-like complications (hazard ratio [HR] 3.8; p = 0.0007), need for surgical/endoscopic interventions [HR 4.1; p = 0.002], and immunosuppressive therapy [HR 5.0; p = 0.0002].
CONCLUSIONS CONCLUSIONS
Pre-pouch ileitis is associated with a higher risk of complicated disease and pouch failure than pouchitis. It should be considered a feature of CD.

Identifiants

pubmed: 33300546
pii: 6029421
doi: 10.1093/ecco-jcc/jjaa251
pmc: PMC8218713
doi:

Substances chimiques

Immunosuppressive Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

960-968

Subventions

Organisme : NIDDK NIH HHS
ID : U01 DK062413
Pays : United States

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Références

J Crohns Colitis. 2018 Feb 28;12(3):273-279
pubmed: 29240877
Appl Health Econ Health Policy. 2019 Feb;17(1):77-91
pubmed: 30259396
J Gastrointest Surg. 2011 Sep;15(9):1556-61
pubmed: 21725838
Inflamm Bowel Dis. 2019 Mar 14;25(4):767-774
pubmed: 30295784
Gastroenterology. 2004 Jun;126(7):1686-91
pubmed: 15188163
Aliment Pharmacol Ther. 2016 Oct;44(8):807-16
pubmed: 27534519
Inflamm Bowel Dis. 2020 Jun 18;26(7):1079-1086
pubmed: 31587035
Inflamm Bowel Dis. 2019 Feb 21;25(3):460-471
pubmed: 30124882
Gut. 2006 Jun;55(6):749-53
pubmed: 16698746
Inflamm Bowel Dis. 2019 Aug 20;25(9):1569-1576
pubmed: 30810748
Aliment Pharmacol Ther. 2009 Jan;29(1):69-74
pubmed: 18945262
Inflamm Bowel Dis. 2016 Jun;22(6):1502-8
pubmed: 27057684
Inflamm Bowel Dis. 2017 May;23(5):781-790
pubmed: 28301429
Inflamm Bowel Dis. 2015 Jan;21(1):110-20
pubmed: 25437817
Am Surg. 2016 Oct;82(10):977-981
pubmed: 27779987
Dis Colon Rectum. 2009 May;52(5):879-83
pubmed: 19502851
Clin Exp Gastroenterol. 2018 Dec 11;11:461-465
pubmed: 30588057
Inflamm Bowel Dis. 2018 Jan 18;24(2):261-268
pubmed: 29361101
Inflamm Bowel Dis. 2016 Mar;22(3):662-8
pubmed: 26383915
Inflamm Bowel Dis. 2019 Aug 20;25(9):1474-1480
pubmed: 30698715
Dis Colon Rectum. 2018 Apr;61(4):472-475
pubmed: 29369899
Inflamm Bowel Dis. 2011 Sep;17(9):1890-900
pubmed: 21830267
Clin Gastroenterol Hepatol. 2013 Dec;11(12):1538-49
pubmed: 23602818

Auteurs

Gaurav Syal (G)

F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Ron Shemtov (R)

Sackler School of Medicine, Tel Aviv, Israel.

Nirupama Bonthala (N)

F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Eric A Vasiliauskas (EA)

F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Edward J Feldman (EJ)

F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Karen Zaghiyan (K)

Division of Colorectal Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Christina Y Ha (CY)

F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Dermot P B McGovern (DPB)

F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Stephan R Targan (SR)

F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Gil Y Melmed (GY)

F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Phillip R Fleshner (PR)

F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Division of Colorectal Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH